The Effect of Intravitreal Bevacizumab Injection in Wet Age-Related Macular Degeneration Patients with Cataract Surgery
- Author:
Jae-Hong AN
1
;
Yu-Cheol KIM
;
Kyung Tae KANG
Author Information
- Publication Type:Original Article
- From:Keimyung Medical Journal 2023;42(1):44-51
- CountryRepublic of Korea
- Language:Korean
- Abstract: This study was design to evaluate the efficacy of cataract surgery with simultaneous intravitreal bevacizumab injection for wet age-related macular degeneration. Of the patients who underwent anti-vascular endothelial growth factor injections, cataract surgery was performed in 24 eyes (control group), and simultaneous intravitreal bevacizumab injection was performed in 27 eyes (bevacizumab group). Best corrected visual acuity, ocular tonometry, anterior chamber inflammation, and central subfield macular thickness were measured at baseline and 1 week, 1 month, 3 months, and 6 months after surgery. The mean central subfield macular thickness increased 1 month postoperatively in the control group (p = 0.02), whereas there was no significant change in the bevacizumab group. When the preoperative and postoperative differences between the two groups were compared at each time point, the mean best corrected visual acuity improved in the bevacizumab group at 3 months after surgery (p = 0.045), and the mean central subfield macular thickness was more decreased in the bevacizumab group at 1 month after surgery compared to that of the control group (p = 0.032). Additional anti-vascular endothelial growth factor injection was performed after surgery at 1.56 ± 2.05 months and 2.52 ± 2.01 months, in the control and bevacizumab groups, respectively (p = 0.047). Simultaneous cataract surgery and intravitreal bevacizumab injection is considered an effective treatment since it reduces central subfield macular thickness in the short term, and it can delay the timing of additional anti-vascular endothelial growth factor injections after surgery.
